Could removing a mole help treat vitiligo? new trial aims to find out

NCT ID NCT07307534

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether surgically removing the central mole (halo nevus) in people with vitiligo leads to better skin color restoration than using medication alone. Sixty participants aged 6 to 45 will be randomly assigned to either have the mole removed plus standard treatment, or receive only standard treatment. The trial will track repigmentation over 6 months to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Central nevus excision (surgery or laser) plus standard medication (tacrolimus ointment and NB-UVB phototherapy, with possible oral prednisone)
What this could lead to
If successful, this could show that removing the central nevus improves repigmentation in vitiligo patients with halo nevi, offering a better treatment approach.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. Surgery carries risks like scarring or infection, and the benefit over medication alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HALO NEVUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xijing Hospital

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.